Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3462 | SBRT Wiki | 1.00 |
| drug1490 | FLT3 Ligand (CDX-301) Wiki | 1.00 |
| drug1030 | Control Wiki | 0.28 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D002289 | Carcinoma, Non-Small-Cell Lung NIH | 0.45 |
| D008175 | Lung Neoplasms NIH | 0.29 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0030358 | Non-small cell lung carcinoma HPO | 0.45 |
| HP:0100526 | Neoplasm of the lung HPO | 0.29 |
Navigate: Correlations HPO
There is one clinical trial.
The purpose of this study is to test a new way of treating the most common form of lung cancer. The investigators are testing a combination of radiotherapy with two new forms of immunotherapy. This study is testing the safety and effectiveness of this treatment approach as compared to standard treatment options.
Description: Death Any ≥ Grade 3 non-hematological toxicity, with the following exceptions: Grade 3 alopecia, vitiligo, or endocrinopathies controlled by hormone replacement therapy Grade 3 nausea that resolves to ≤ grade 2 with or without treatment within 72 hours Grade 3 vomiting and diarrhea that resolves to ≤ grade 2 with or without treatment within 72 hours Grade 3 fatigue that resolves to ≤ grade 2 within 5 days Grade 3 hypertension in the absence of maximal medical therapy Grade 3 adverse event of tumor flare (defined as local pain, irritation, or rash localized at sites of known or suspected tumor) of ≤ 7 days in duration Grade 3 amylase or lipase abnormalities that are not associated with symptoms or clinical manifestations of pancreatitis. It is recommended to consult with the Principal Investigator for grade 4 amylase or lipase abnormalities Grade 3 clinically significant laboratory abnormalities that are asymptomatic and can be reversed within 72 hours, however: Any Grade 4
Measure: Phase I: Dose-limiting toxicity (DLT), defined as follows: Time: up to 8 weeks after initiation of study therapyDescription: Length of time that patient survives from time of study registration
Measure: Overall survival (OS) duration Time: From date of registration until the date of death from any cause, assessed up to 2 yearsDescription: The clinical benefit rate (CBR) will be defined as the percentage of subjects who achieve best response of confirmed CR or PR, or stable disease (SD) for at least four months.
Measure: Radiographic responses using descriptive statistics Time: From date of registration, assessed up to 4 monthsDescription: Summary statistics (mean, standard deviation, median, 25th and 75th percentiles, and range) and the mean change from baseline of linear-transformed scores will be reported for all the items and subscales of the EORTC QLQ-C30 questionnaire and the QLQ-LC13, according to the EORTC scoring manual guidelines. higher scores are a better level of functioning
Measure: Quality of Life using EORTC QLQ-LC13 (quality of Life Questionnaire, Lung Cancer) Time: 1 yearDescription: Summary statistics (mean, standard deviation, median, 25th and 75th percentiles, and range) and the mean change from baseline of linear-transformed scores will be reported for all the items and subscales of the EORTC QLQ-C30 questionnaire and the QLQ-LC13, according to the EORTC scoring manual guidelines. Most items are scored 1 to 4, higher scores are a better level of functioning.
Measure: Quality of Life using QLQ-C30 (Quality of Life Questionnaire) Time: 1 yearDescription: Average daily step counts
Measure: Daily step count using descriptive statistics Time: 1 yearAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports